Antiviral compounds
AssigneeThe Regents of the University of California
InventorJeffrey S. Glenn
Life of this patent
Estimating the term…
Abstract
The macrolide FK506, produced by Fujisawa Pharmaceuticals is effective in inhibiting the replication of hepatitis D virus. It is believed that replication is inhibited either by virtue of the ability of FK506 to inhibit proline isomerase or otherwise to interfere with the function of a C-terminal proline in a replication factor or by virtue of its interference with RNA replication directly.
Claims5
A method to inhibit the replication of a virus that requires proline isomerase for replication, said method comprises the step of contacting a cell in which said virus replicates with an amount of a proline isomerase inhibitor sufficient to inhibit replication.
A method to inhibit the replication of a virus that requires proline isomerase for replication, said method comprises the step of contacting a cell in which said virus replicates with an amount of a compound of the formula:
- ##STR2## or a pharmaceutically acceptable acyl (1-6C) ester thereof sufficient to inhibit replication.
A method to inhibit the replication of a virus that requires proline isomerase for replication, said method comprises the step of contacting a cell in which said virus replicates with an mount of a compound selected from the group consisting of FK506 rapamycin and 506BD sufficient to inhibit replication.
A method to inhibit the replication of hepatitis D virus, said method comprises the step of contacting a cell in which said virus replicates with an amount of a proline isomerase inhibitor sufficient to inhibit replication.
A method to inhibit the replication of hepatitis D virus, said method comprises the step of contacting a cell in which said virus replicates with an amount of a compound of the formula sufficient to inhibit replication:
- ##STR3## or a pharmaceutically acceptable acyl (1-6C) ester thereof sufficient to inhibit replication.
Dependencies are inferred from the claim text.